Meta-Analysis of the Immunogenicity and Tolerability of Pandemic Influenza A 2009 (H1N1) Vaccines

Background Although the 2009 (H1N1) influenza pandemic officially ended in August 2010, the virus will probably circulate in future years. Several types of H1N1 vaccines have been tested including various dosages and adjuvants, and meta-analysis is needed to identify the best formulation. Methods We searched MEDLINE, EMBASE, and nine clinical trial registries to April 2011, in any language for randomized clinical trials (RCTs) on healthy children, adolescents, adults and the elderly. Primary outcome was the seroconversion rate according to hemagglutinination-inhibition (HI); secondary outcomes were adverse events. For the primary outcome, we used head-to-head meta-analysis and multiple-treatments meta-analysis. Results Eighteen RCTs could be included in all primary analyses, for a total of 76 arms (16,725 subjects). After 2 doses, all 2009 H1N1 split/subunit inactivated vaccines were highly immunogenic and overcome CPMP seroconversion criteria. After 1 dose only, all split/subunit vaccines induced a satisfactory immunogenicity (> = 70%) in adults and adolescents, while only some formulations showed acceptable results for children and elderly (non-adjuvanted at high-doses and oil-in-water adjuvanted vaccines). Vaccines with oil-in-water adjuvants were more immunogenic than both nonadjuvanted and aluminum-adjuvanted vaccines at equal doses and their immunogenicity at doses < = 6 µg (even with as little as 1.875 µg of hemagglutinin antigen) was not significantly lower than that achieved after higher doses. Finally, the rate of serious vaccine-related adverse events was low for all 2009 H1N1 vaccines (3 cases, resolved in 10 days, out of 22826 vaccinated subjects). However, mild to moderate adverse reactions were more (and very) frequent for oil-in-water adjuvanted vaccines. Conclusions Several one-dose formulations might be valid for future vaccines, but 2 doses may be needed for children, especially if a low-dose non-adjuvanted vaccine is used. Given that 15 RCTs were sponsored by vaccine manufacturers, future trials sponsored by non-industry agencies and comparing vaccines using different types of adjuvants are needed.

[1]  G. Leroux-Roels,et al.  Effect on Cellular and Humoral Immune Responses of the AS03 Adjuvant System in an A/H1N1/2009 Influenza Virus Vaccine Administered to Adults during Two Randomized Controlled Trials , 2011, Clinical and Vaccine Immunology.

[2]  H. Ikematsu,et al.  Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan , 2010, Human vaccines.

[3]  Ming Wang,et al.  Immunogenicity Associated with the Routine Use of an Influenza A H1N1 Vaccine in Health Care Personnel in Guangzhou, China , 2010, Clinical and Vaccine Immunology.

[4]  Kazuo Suzuki,et al.  Immunogenicity of a monovalent pandemic influenza A H1N1 vaccine in health‐care workers of a university hospital in Japan , 2010, Microbiology and immunology.

[5]  P. Villari,et al.  Methodological quality of studies and patient age as major sources of variation in efficacy estimates of influenza vaccination in healthy adults: a meta-analysis. , 2004, Vaccine.

[6]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[7]  J. Arístegui,et al.  Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months. , 2010, Vaccine.

[8]  Douglas G Altman,et al.  Systematic reviews in health care: Assessing the quality of controlled clinical trials. , 2001, BMJ.

[9]  Wen-Sen Lee,et al.  A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza. , 2010, Vaccine.

[10]  I. Olkin,et al.  The case of the misleading funnel plot , 2006, BMJ : British Medical Journal.

[11]  G. D. Cioppa,et al.  Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age , 2011, Human vaccines.

[12]  W. Lim,et al.  Immunogenicity and safety of a two-dose schedule of whole-virion and AS03(A)-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial , 2011 .

[13]  R. Gasparini,et al.  Impact of prior or concomitant seasonal influenza vaccination on MF59‐adjuvanted H1N1v vaccine (Focetria™) in adult and elderly subjects , 2010, International journal of clinical practice.

[14]  Georgia Salanti,et al.  Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. , 2011, Journal of clinical epidemiology.

[15]  H. Kelly,et al.  Large trials confirm immunogenicity of H1N1 vaccines , 2010, The Lancet.

[16]  K. Matsushita,et al.  Comparison of half and full doses of an MF59-adjuvanted cell culture-derived A/H1N1v vaccine in Japanese children , 2010, Advances in therapy.

[17]  Antonio Boccia,et al.  The Efficacy of Influenza Vaccine for Healthy Children: A Meta-Analysis Evaluating Potential Sources of Variation in Efficacy Estimates Including Study Quality , 2007, The Pediatric infectious disease journal.

[18]  X. Zhang,et al.  A novel influenza A (H1N1) vaccine in various age groups. , 2009, The New England journal of medicine.

[19]  R. Betts,et al.  Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. , 1999, Vaccine.

[20]  P. van Damme,et al.  AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  Yan Liu,et al.  A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial. , 2010, The Journal of infectious diseases.

[22]  J. Devaster,et al.  Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. , 2010, Vaccine.

[23]  O. Vanderkooi,et al.  Evaluation of Adjuvanted Pandemic H1N12009 Influenza Vaccine After One and Two Doses in Young Children , 2011, The Pediatric infectious disease journal.

[24]  Xiaofeng Liang,et al.  Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial , 2010, The Lancet.

[25]  G. Kemble,et al.  Safety and Immunogenicity Following Administration of a Live, Attenuated Monovalent 2009 H1N1 Influenza Vaccine to Children and Adults in Two Randomized Controlled Trials , 2010, PloS one.

[26]  J. Ioannidis,et al.  Can quality of clinical trials and meta-analyses be quantified? , 1998, The Lancet.

[27]  K. Koram,et al.  Malaria vaccine development: An endemic country perspective , 2010, Human vaccines.

[28]  Young-Joo Ahn,et al.  Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial. , 2010, Vaccine.

[29]  G. Lu,et al.  Combination of direct and indirect evidence in mixed treatment comparisons , 2004, Statistics in medicine.

[30]  Zhong Huang,et al.  Immune Protection Induced on Day 10 Following Administration of the 2009 A/H1N1 Pandemic Influenza Vaccine , 2010, PloS one.

[31]  S. Faust,et al.  Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study , 2010, BMJ : British Medical Journal.

[32]  Weizhong Yang,et al.  Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China. , 2011, The New England journal of medicine.

[33]  René Ecochard,et al.  Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model , 2010, BMC medical research methodology.

[34]  R. Karron,et al.  A single dose of unadjuvanted novel 2009 H1N1 vaccine is immunogenic and well tolerated in young and elderly adults. , 2010, The Journal of infectious diseases.

[35]  Thomas A Trikalinos,et al.  The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey , 2007, Canadian Medical Association Journal.

[36]  J. Stockman.  Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials , 2011 .

[37]  Georgia Salanti,et al.  Evaluation of networks of randomized trials , 2008, Statistical methods in medical research.

[38]  R. Booy,et al.  Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta‐analysis , 2011, Influenza and other respiratory viruses.

[39]  Y. Hsieh,et al.  Serological response and persistence in schoolchildren with high baseline seropositive rate after receiving 2009 pandemic influenza A(H1N1) vaccine. , 2011, Vaccine.

[40]  Eric Plennevaux,et al.  Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial. , 2011, Vaccine.

[41]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[42]  John Ioannidis,et al.  Exploring the Geometry of Treatment Networks , 2008, Annals of Internal Medicine.

[43]  C. Chiu,et al.  Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents. , 2010, Vaccine.

[44]  A. Arguedas,et al.  Responses to 2009 H1N1 vaccine in children 3 to 17 years of age. , 2010, The New England journal of medicine.

[45]  K. Hoschler,et al.  Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. , 2009, The New England journal of medicine.

[46]  A. A. Romanova,et al.  [Study of tolerability and reactogenicity of pandemic vaccines against influenza type A/H1N1]. , 2010, Zhurnal mikrobiologii, epidemiologii, i immunobiologii.

[47]  R. Cox,et al.  An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. , 2010, Vaccine.

[48]  Wen-Sen Lee,et al.  Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly. , 2010, Vaccine.

[49]  W. Dupont,et al.  A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. , 1994, The Journal of infectious diseases.

[50]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[51]  M. Kieny,et al.  The 2009 A (H1N1) influenza virus pandemic: A review. , 2010, Vaccine.

[52]  Z. Vajo,et al.  Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009–10 influenza season: a multicentre, randomised controlled trial , 2010, The Lancet.

[53]  J. McVernon,et al.  Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. , 2010, JAMA.

[54]  James Singleton,et al.  Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009-January 31, 2010. , 2010, Vaccine.

[55]  조영신,et al.  IT KOREA 미래전략 , 2009 .

[56]  S. Esposito,et al.  Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. , 2011, Vaccine.

[57]  Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. , 2010, Releve epidemiologique hebdomadaire.

[58]  Nikolaos A Patsopoulos,et al.  Uncertainty in heterogeneity estimates in meta-analyses , 2007, BMJ : British Medical Journal.

[59]  John P.A. Ioannidis,et al.  Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses , 2009, Canadian Medical Association Journal.

[60]  C. N. Brorn,et al.  WHO? , 1896 .

[61]  J. Noh,et al.  Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea. , 2011, Vaccine.

[62]  W. Lim,et al.  Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. , 2011, The Lancet. Infectious diseases.

[63]  Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study. , 2011, Vaccine.

[64]  J. McVernon,et al.  Panvax®: a monovalent inactivated unadjuvanted vaccine against pandemic influenza A (H1N1) 2009 , 2011, Expert review of vaccines.

[65]  J. Ioannidis,et al.  Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis. , 2009, The Lancet. Infectious diseases.

[66]  C. Wichems,et al.  Response to a monovalent 2009 influenza A (H1N1) vaccine. , 2009, The New England journal of medicine.

[67]  S Dias,et al.  Checking consistency in mixed treatment comparison meta‐analysis , 2010, Statistics in medicine.